Literature DB >> 3631983

Prognostic significance of hypopigmentation in malignant melanoma.

J C Bystryn, D Rigel, R J Friedman, A Kopf.   

Abstract

It has been suggested that the presence of cutaneous hypopigmentation favorably influences the prognosis of patients with malignant melanoma (MM). To examine this possibility, we have compared the actual with the predicted survival of 46 patients with MM and hypopigmentation who were among 1130 patients with MM entered in a long-term prospective study of MM at the New York University Medical Center. The actual average five-year survival rate of the patients with MM and hypopigmentation (86.3%) was significantly better than predicted (74.8%) on the basis of the risk factors present in each patient at the time of entry into the study. The findings suggest that hypopigmentation is a factor that beneficially influences the prognosis of MM, and that the mechanisms that inhibit or destroy normal melanocytes in patients with MM may also slow the growth of this cancer.

Entities:  

Mesh:

Year:  1987        PMID: 3631983

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  54 in total

Review 1.  Prognostic significance of autoimmunity during treatment of melanoma with interferon.

Authors:  Michal T Krauze; Ahmad Tarhini; Helen Gogas; John M Kirkwood
Journal:  Semin Immunopathol       Date:  2011-01-31       Impact factor: 9.623

Review 2.  Melanoma-associated leukoderma - immunology in black and white?

Authors:  Hadas Prag Naveh; Uma N M Rao; Lisa H Butterfield
Journal:  Pigment Cell Melanoma Res       Date:  2013-10-09       Impact factor: 4.693

3.  Progression of Cutaneous Vitiligo in a Patient with Large Posterior Choroidal Melanoma: A Case Report.

Authors:  Angela Ding; Javier Elizalde; Rafael Ignacio Barraquer
Journal:  Ocul Oncol Pathol       Date:  2015-04-01

4.  Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.

Authors:  Katelyn T Byrne; Peisheng Zhang; Shannon M Steinberg; Mary Jo Turk
Journal:  J Immunol       Date:  2014-01-08       Impact factor: 5.422

Review 5.  Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications.

Authors:  Ami A Shah; Antony Rosen
Journal:  Curr Opin Rheumatol       Date:  2011-11       Impact factor: 5.006

Review 6.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

7.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

8.  Vitiligo- and melanoma-associated hypopigmentation: a similar appearance but a different mechanism.

Authors:  O Merimsky; Y Shoenfeld; G Yecheskel; S Chaitchik; E Azizi; P Fishman
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

9.  Skeletal muscle phenotypically converts and selectively inhibits metastatic cells in mice.

Authors:  Ara Parlakian; Iman Gomaa; Sounkary Solly; Ludovic Arandel; Alka Mahale; Gustav Born; Giovanna Marazzi; David Sassoon
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

10.  Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial.

Authors:  Helen Gogas; Urania Dafni; Henry Koon; Maria Spyropoulou-Vlachou; Yannis Metaxas; Elizabeth Buchbinder; Eirini Pectasides; Dimosthenis Tsoutsos; Aristidis Polyzos; Alexandros Stratigos; Christos Markopoulos; Petros Panagiotou; George Fountzilas; Ourania Castana; Pantelis Skarlos; Michael B Atkins; John M Kirkwood
Journal:  J Transl Med       Date:  2010-11-03       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.